1. Clinical validation of a biopsy‐based six‐gene signature prognostic for aggressive prostate cancer
- Author
-
Agnieszka Krzyzanowska, Debra F. Higgins, Stephen Barron, Tony Loughman, Amanda O'Neill, Katherine M. Sheehan, Chan‐Ju Angel Wang, Bozena Fender, Leah McGuire, Joanna Fay, Anthony O'Grady, Des O'Leary, R. William Watson, Anders Bjartell, and William M. Gallagher
- Subjects
gene expression signature ,molecular risk score ,patient management ,prognosis ,prostate cancer ,risk stratification ,Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Abstract Objectives This study aimed to clinically validate the six‐gene prognostic molecular clinical risk score (MCRS) for the prediction of aggressive prostate cancer in diagnostic biopsy tissue. Methods MCRS was evaluated in prostate biopsy tissue from a Swedish cohort of men with prostate cancer (UPCA, n = 100). The primary outcome of adverse pathology and secondary outcomes of high primary Gleason (≥G4) and high pathological T‐stage (≥T3) were assessed by likelihood ratio statistics and area under the receiver operating characteristic curves from logistic regression models; time to biochemical recurrence was assessed by likelihood ratio statistics and C‐indexes from Cox proportional hazard regression models. Results Biopsy MCRS was significantly prognostic (p
- Published
- 2025
- Full Text
- View/download PDF